Preview

Кардиология

Расширенный поиск

Проблема тромбоза у пациентов со злокачественными заболеваниями

https://doi.org/10.18087/cardio.2523

Полный текст:

Аннотация

На протяжении десятилетий тромбоз рассматривался как осложнение ССЗ, однако данная проблема долгое время редко принималась во внимание при наличии рака. Хотя связь между онкологическим заболеванием и тромбозом была признана почти 150 лет назад, только недавно сложилось мнение, что рак является протромботическим заболеванием. Тромбоз для многих пациентов становится одним из первых и ранних симптомов рака и в то же время считается частой причиной смерти у онкобольных. Тромботические события оказывают значимое влияние на качество жизни пациентов, ухудшают краткосрочный и долгосрочный прогнозы. Последние исследования показали рост частоты тромбоза, ассоциированного с раком. Цель данного обзора - обобщить современные взгляды на патофизиологию, а также изложить новые подходы к оценке риска, профилактике и лечению тромбоза при онкологических заболеваниях.

Об авторах

Е. В. Плохова
ФГБУ «Федеральный научно-клинический центр специализированных видов медицинской помощи и медицинских технологий ФМБА России»
Россия


Д. П. Дундуа
ФГБУ «Федеральный научно-клинический центр специализированных видов медицинской помощи и медицинских технологий ФМБА России»
Россия


Список литературы

1. Piccioli A, Prandoni P. Idiopathic venous thromboembolism as a first manifestation of cancer. Haemostasis. 2001;31 Suppl 1:37-9. PMID:11990473

2. Trousseau A. Phlegmasia alba dolens. Clinique medicale de 1’ Hotel-Dieu de Paris. 2nd ed. -Paris: Ballière; 1865. 878 p.

3. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. Journal of Thrombosis and Haemostasis. 2007;5 (3):632-4. DOI:10.1111 / j. 15387836.2007.02374. x

4. Streiff MB, Holmstrom B, Ashrani A, Bockenstedt PL, Chesney C, Eby C et al. Cancer-Associated Venous Thromboembolic Disease, Version 1.2015. J Natl Compr Canc Netw. 2015;13 (9):1079-95. PMID:26358792

5. RakJ, Yu JL, Luyendyk J, Mackman N. Oncogenes, Trousseau Syndrome, and Cancer-Related Changes in the Coagulome of Mice and Humans. Cancer Research. 2006;66 (22):10643-6. DOI:10.1158/0008-5472. CAN-06-2350

6. Gupta PK, Charan VD, Kumar H. Cancer related thrombophilia: clinical importance and management strategies. J Assoc Physicians India. 2005;53:877-82. PMID:16459532

7. Rickles FR. Mechanisms of cancer-induced thrombosis in cancer. Pathophysiol Haemost Thromb. 2006;35 (1-2):103-10. DOI:10.1159/000093551

8. Riedl J, Hell L, Kaider A, Koder S, Marosi C, Zielinski C et al. Association of platelet activation markers with cancer-associated venous thromboembolism. Platelets. 2016;27 (1):80-5. DOI:10.3109/095 37104.2015.1041901

9. Ay C, Simanek R, Vormittag R, Dunkler D, Alguel G, Koder S et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood. 2008;112 (7):2703-8. DOI: 10.1182/blood-2008-02-142422

10. Simanek R, Vormittag R, Ay C, Alguel G, Dunkler D, Schwarzinger I et al. High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Journal of Thrombosis and Haemostasis. 2010;8 (1):114-20. DOI:10.1111/j. 1538-7836.2009.03680. x

11. Meikle CKS, Kelly CA, Garg P, Wuescher LM, Ali RA., Worth RG. Cancer and Thrombosis: The Platelet Perspective. Frontiers in Cell and Developmental Biology [Internet]. 2017 [cited 2018];4. DOI: 10.3389/fcell. 2016.00147

12. Ji W, Chen J, Mi Y, Wang G, Xu X, Wang W. Platelet-activating factor receptor activation promotes prostate cancer cell growth, invasion and metastasis via ERK1/2 pathway. International Journal of Oncology. 2016;49 (1):181-8. DOI:10.3892/ijo. 2016.3519

13. Rak J, Milsom C, May L, Klement P, Yu J. Tissue Factor in Cancer and Angiogenesis: The Molecular Link between Genetic Tumor Progression, Tumor Neovascularization, and Cancer Coagulopathy. Seminars in Thrombosis and Hemostasis. 2006;32 (01):054-70. DOI:10.1055/s-2006-933341

14. Yu JL. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood. 2005;105 (4):1734-41. DOI:10.1182/blood-2004-05-2 042

15. Rong Y, Post DE, Pieper RO, Durden DL, Van Meir EG, Brat DJ. PTEN and Hypoxia Regulate Tissue Factor Expression and Plasma Coagulation by Glioblastoma. Cancer Research. 2005;65 (4):1406 13. DOI:10.1158/0008-5472. CAN-04-3376

16. Lecumberri R, Marqués M, Panizo E, Alfonso A, Garcia-Mouriz A, Gil-Bazo I et al. High incidence of venous thromboembolism despite electronic alerts for thromboprophylaxis in hospitalised cancer patients. Thrombosis and Haemostasis. 2013;110 (07):184-90. DOI: 10.1160/TH13-02-0131

17. Menapace LA, Peterson DR, Berry A, Sousou T, Khorana AA. Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer. Thrombosis and Haemostasis. 2011,106 (08):371-8. DOI: 10.1160/TH10-12-0789

18. O’Connell CL, Boswell WD, Duddalwar V Caton A, Mark LS, Vigen C et al. Unsuspected Pulmonary Emboli in Cancer Patients: Clinical Correlates and Relevance. Journal of Clinical Oncology. 2006,24 (30):4928-32. DOI:10.1200/JCO. 2006.06.5870

19. Kuenen BC, Rosen L, Smit EF, Parson MRN, Levi M, Ruijter R et al. Dose-Finding and Pharmacokinetic Study of Cisplatin, Gemcitabine, and SU5416 in Patients With Solid Tumors. Journal of Clinical Oncology. 2002,20 (6):1657-67. DOI:10.1200/JCO. 2002.20.6.1657

20. Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. Journal of Clinical Oncology. 1991,9 (2):286-94. DOI:10.1200/JCO. 1991.9.2.286

21. Aronson D, Brenner B. Arterial thrombosis and cancer. Thrombosis Research. 2018,164: S23-8. DOI:10.1016/j. thromres. 2018.01.003

22. Ewer MS, Glück S. A woman’s heart: The impact of adjuvant endocrine therapy on cardiovascular health. Cancer. 2009,115 (9):1813-26. DOI: 10.1002/cncr. 24219

23. Prandoni P. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002,100 (10):3484-8. DOI:10.1182/bl ood-2002-01-0108

24. Zamorano JL, Lancellotti P, Munoz DR, Aboyans V, Asteggiano R, Galderisi M et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Kardiologia Polska. 2016,74 ( 11 ): 1193-233. DOI:10.5603/KP. 2016.0156

25. Königsbrügge O, Pabinger I, Ay C. Risk factors for venous thromboembolism in cancer: novel findings from the Vienna Cancer and Thrombosis Study (CATS). Thrombosis Research. 2014,133: S39 43. DOI:10.1016/S0049-3848 (14) 50007-2

26. Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of Venous Thromboembolism and Its Effect on Survival Among Patients With Common Cancers. Archives of Internal Medicine. 2006,166 (4):458. DOI:10.1001/archinte. 166.4.458

27. Falanga A, Marchetti M, Russo L. Venous thromboembolism in the hematologic malignancies: Current Opinion in Oncology. 2012,24 (6):702-10. DOI:10.1097/CCO. 0b013e3283592331

28. BlomJW, VanderschootJPM, Oostindier MJ, Osanto S, Van Der Meer FJM, Rosendaal FR. Incidence of venous thrombosis in a large cohort of 66329 cancer patients: results of a record linkage study. Journal of Thrombosis and Haemostasis. 2006,4 (3):529-35. DOI:10.1111/j. 1538-7836.2006.01804. x

29. Khorana AA, Connolly GC. Assessing Risk of Venous Thromboembolism in the Patient With Cancer. Journal of Clinical Oncology. 2009,27 (29):4839-47. DOI:10.1200/JCO. 2009.22.3271

30. Chang H-M, Okwuosa TM, Scarabelli T, Moudgil R, Yeh ETH. Cardiovascular Complications of Cancer Therapy. Journal of the American College of Cardiology. 2017,70 (20):2552-65. DOI:10.1016/j. jacc. 2017.09.1095

31. Agnelli G, Bolis G, Capussotti L, Scarpa RM, Tonelli F, Bonizzoni E et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg. 2006,243 (1):89-95. PMID:16371741

32. Tesselaar MET, Ouwerkerk J, Nooy MA, Rosendaal FR, Osanto S. Risk factors for catheter-related thrombosis in cancer patients. European Journal of Cancer. 2004,40 (15):2253-9. DOI:10.1016/j. ejca. 2004.06.023

33. Ay C, Vormittag R, Dunkler D, Simanek R, Chiriac A-L, Drach J et al. D-Dimer and Prothrombin Fragment 1 + 2 Predict Venous Thromboembolism in Patients With Cancer: Results From the Vienna Cancer and Thrombosis Study. Journal of Clinical Oncology. 2009,27 (25):4124-9. DOI:10.1200/JCO. 2008.21.7752

34. Thaler J, Ay C, Mackman N, Bertina RM, Kaider A, Marosi C et al. Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients: MP-TF activity, VTE and mortality in cancer. Journal of Thrombosis and Haemostasis. 2012;10 (7):1363-70. DOI: 10.1111 /j. 1538-7836.2012.04754. x

35. Farge D, Bounameaux H, Brenner B, Cajfinger F, Debourdeau P, Khorana AA et al. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. The Lancet Oncology. 2016;17 (10):e452-66. DOI:10.1016/S1470-2045 (16) 30369-2

36. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111 (10):4902-7. DOI:10.1182/ blood-2007-10-116327

37. Ay C, Dunkler D, Marosi C, Chiriac A-L, Vormittag R, Simanek R et al. Prediction of venous thromboembolism in cancer patients. Blood. 2010;116 (24):5377-82. DOI:10.1182/blood-2010-02-270116

38. van Es N, Di Nisio M, Cesarman G, Kleinjan A, Otten H-M, Mahé I et al. Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study. Haematologi-ca. 2017;102 (9):1494-501. DOI:10.3324/haematol. 2017.169060

39. van Es N, Franke VF, Middeldorp S, Wilmink JW, Büller HR. The Khorana score for the prediction of venous thromboembolism in patients with pancreatic cancer. Thrombosis Research. 2017;150:30-2. DOI:10.1016/j. thromres. 2016.12.013

40. Akl EA, Kahale LA, Barba M, Neumann I, Labedi N, Terrenato I et al. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group, editor. Cochrane Database of Systematic Reviews [Internet]. 2014 [cited 2018]; DOI:10.1002/14651858. CD006650. pub4

41. Hakoum MB, Kahale LA, Tsolakian IG, Matar CF, Yosuico VE, Terrenato I et al. Anticoagulation for the initial treatment of venous thromboembolism in people with cancer. Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group, editor. Cochrane Database of Systematic Reviews [Internet]. 2018 [cited 2018]; DOI:10.1002/14651858. CD006649. pub7

42. Prins MH, Lensing AW, Bauersachs R, van Bellen B, Bounameaux H, Brighton TA et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal. 2013;11 (1):21. DOI:10.1186/1477-9560-11-21

43. Schulman S, Goldhaber SZ, Kearon C, Kakkar AK, Schellong S, Eriksson H et al. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thrombosis and Haemostasis. 2015;114 (07):150-7. DOI:10.1160/TH14-11-0977

44. Agnelli G, Buller HR, Cohen A, Gallus AS, Lee TC, Pak R et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis. 2015;13 (12):2187-91. DOI:10.1111/jth. 13153

45. Raskob GE, van Es N, Segers A, Angchaisuksiri P, Oh D, Boda Z et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. The Lancet Haematology. 2016;3 (8):e379-87. DOI:10.1016/S2352-3026 (16) 30057-6

46. Lee AYY, Carrier M. Treatment of cancer-associated thrombosis: perspectives on the use of novel oral anticoagulants. Thrombosis Research. 2014;133: S167-71. DOI:10.1016/S0049-3848 (14) 50027-8

47. Barginear MF, Gralla RJ, Bradley TP, Ali SS, Shapira I, Greben C et al. Investigating the benefit of adding a vena cava filter to anticoagulation with fondaparinux sodium in patients with cancer and venous thromboembolism in a prospective randomized clinical trial. Supportive Care in Cancer. 2012;20 (11):2865-72. DOI:10.1007/s00520-012-1413-z

48. Villemur B, Payraud E, Seetha V, De Angelis M-P, Magne JL, Perennou D et al. Thromboses itératives de pontages artériels et cancer: à propos de trois cas. Journal des Maladies Vasculaires. 2014;39 (1):14-7. DOI:10.1016/j. jmv. 2013.09.003


Для цитирования:


Плохова Е.В., Дундуа Д.П. Проблема тромбоза у пациентов со злокачественными заболеваниями. Кардиология. 2018;58(9S):19-28. https://doi.org/10.18087/cardio.2523

For citation:


Plokhova E.V., Dundua D.P. Thrombosis in patients with malignancy. Kardiologiia. 2018;58(9S):19-28. (In Russ.) https://doi.org/10.18087/cardio.2523

Просмотров: 81


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 0022-9040 (Print)
ISSN 2412-5660 (Online)